{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
fosdenopterin
to a specific field?
There is one exact (name or code) match for fosdenopterin
Status:
US Approved Rx
(2021)
Source:
NDA214018
(2021)
Source URL:
First approved in 2021
Source:
NDA214018
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cyclic pyranopterin monophosphate is a precursor to molybdenum cofactor, which is required for the enzyme activity of sulfite oxidase, xanthine dehydrogenase/oxidase, and aldehyde oxidase. The drug is being investigated in severe molybdenum cofactor deficiency type A. In a clinical study, intravenous administration of the drug resulted in greatly improved neurodevelopmental outcome when started sufficiently early.
Showing 1 - 6 of 6 results
Status:
US Approved Rx
(2021)
Source:
NDA214018
(2021)
Source URL:
First approved in 2021
Source:
NDA214018
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cyclic pyranopterin monophosphate is a precursor to molybdenum cofactor, which is required for the enzyme activity of sulfite oxidase, xanthine dehydrogenase/oxidase, and aldehyde oxidase. The drug is being investigated in severe molybdenum cofactor deficiency type A. In a clinical study, intravenous administration of the drug resulted in greatly improved neurodevelopmental outcome when started sufficiently early.
Status:
US Approved Rx
(2023)
Source:
NDA217369
(2023)
Source URL:
First approved in 2023
Source:
NDA217369
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
US Approved Rx
(2021)
Source:
NDA214018
(2021)
Source URL:
First approved in 2021
Source:
NDA214018
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cyclic pyranopterin monophosphate is a precursor to molybdenum cofactor, which is required for the enzyme activity of sulfite oxidase, xanthine dehydrogenase/oxidase, and aldehyde oxidase. The drug is being investigated in severe molybdenum cofactor deficiency type A. In a clinical study, intravenous administration of the drug resulted in greatly improved neurodevelopmental outcome when started sufficiently early.
Status:
US Approved Rx
(2021)
Source:
NDA214018
(2021)
Source URL:
First approved in 2021
Source:
NDA214018
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cyclic pyranopterin monophosphate is a precursor to molybdenum cofactor, which is required for the enzyme activity of sulfite oxidase, xanthine dehydrogenase/oxidase, and aldehyde oxidase. The drug is being investigated in severe molybdenum cofactor deficiency type A. In a clinical study, intravenous administration of the drug resulted in greatly improved neurodevelopmental outcome when started sufficiently early.